Iclusig Approved for CML and ALL (January 4, 2013)
The U.S. Food and Drug Administration (FDA) has approved Iclusig™ (ponatinib) to treat adults with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+... Continue Reading
Blinatumomab induces high complete remission rates and prolongs survival in adult patients with relapsed/refractory B-precursor acute lymphoblastic lymphoma (ALL), according to the results of a study presented... Continue Reading
The U.S. Food and Drug Administration (FDA) has approved Marqibo® (vincristine sulfate liposome injection) to treat adults with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL)... Continue Reading
A subset of young patients with acute lymphoblastic leukemia (ALL) who fail to achieve remission after the initial weeks of intense chemotherapy known as induction therapy appear to have better outcomes... Continue Reading
Between 1990 and 2005, five-year survival for children and adolescents with acute lymphoblastic leukemia (ALL) increased from 83.7 percent to 90.4 percent. These results were published in the Journal of... Continue Reading
The US Food and Drug Administration (FDA) announced that Sprycel® (dasatinib) may increase the risk of a rare but serious condition known as pulmonary arterial hypertension. Sprycel is a targeted therapy... Continue Reading
Researchers involved in a multi-center US trial have reported that inotuzumab ozogamicin “is likely the single most active single agent tested so far in patients with R-R ALL”. The details of this... Continue Reading
For children and young adults with high-risk, B-precursor acute lymphoblastic leukemia (ALL), high-dose methotrexate resulted in fewer relapses than the standard regimen of escalating methotrexate. The... Continue Reading
A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients.... Continue Reading
A recent study suggests that methylphenidate may provide long-term cognitive benefits to children who have been treated for brain cancer or acute lymphoblastic leukemia (ALL). These findings were published... Continue Reading